Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 135

1.

Influence of sildenafil and tadalafil on the enzyme- and transporter-inducing effects of bosentan and ambrisentan in LS180 cells.

Weiss J, Theile D, Spalwisz A, Burhenne J, Riedel KD, Haefeli WE.

Biochem Pharmacol. 2013 Jan 15;85(2):265-73. doi: 10.1016/j.bcp.2012.11.020. Epub 2012 Dec 5.

PMID:
23219525
[PubMed - indexed for MEDLINE]
2.

Differential modulation of the expression of important drug metabolising enzymes and transporters by endothelin-1 receptor antagonists ambrisentan and bosentan in vitro.

Weiss J, Herzog M, Haefeli WE.

Eur J Pharmacol. 2011 Jun 25;660(2-3):298-304. doi: 10.1016/j.ejphar.2011.04.003. Epub 2011 Apr 9.

PMID:
21501604
[PubMed - indexed for MEDLINE]
3.

Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes.

Hartman JC, Brouwer K, Mandagere A, Melvin L, Gorczynski R.

Can J Physiol Pharmacol. 2010 Jun;88(6):682-91. doi: 10.1139/Y10-060.

PMID:
20628435
[PubMed - indexed for MEDLINE]
Free Article
4.

Ambrisentan and tadalafil synergistically relax endothelin-induced contraction of rat pulmonary arteries.

Liang F, Yang S, Yao L, Belardinelli L, Shryock J.

Hypertension. 2012 Mar;59(3):705-11. doi: 10.1161/HYPERTENSIONAHA.111.182261. Epub 2012 Feb 6.

PMID:
22311911
[PubMed - indexed for MEDLINE]
Free Article
5.

Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil.

Treiber A, Schneiter R, Häusler S, Stieger B.

Drug Metab Dispos. 2007 Aug;35(8):1400-7. Epub 2007 May 11.

PMID:
17496208
[PubMed - indexed for MEDLINE]
Free Article
6.

Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers.

Spence R, Mandagere A, Dufton C, Venitz J.

J Clin Pharmacol. 2008 Dec;48(12):1451-9. doi: 10.1177/0091270008324180. Epub 2008 Oct 1.

PMID:
18832294
[PubMed - indexed for MEDLINE]
7.

Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.

Montani D, Chaumais MC, Savale L, Natali D, Price LC, Jaïs X, Humbert M, Simonneau G, Sitbon O.

Adv Ther. 2009 Sep;26(9):813-25. doi: 10.1007/s12325-009-0064-z. Epub 2009 Sep 19. Review.

PMID:
19768639
[PubMed - indexed for MEDLINE]
8.

Effects of selective and unselective endothelin-receptor antagonists on prostacyclin synthase gene expression in experimental pulmonary hypertension.

Schroll S, Arzt M, Sebah D, Stoelcker B, Luchner A, Budweiser S, Blumberg FC, Pfeifer M.

Scand J Clin Lab Invest. 2008;68(4):270-6. doi: 10.1080/00365510701673375.

PMID:
18612919
[PubMed - indexed for MEDLINE]
9.

Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.

Dranitsaris G, Mehta S.

Appl Health Econ Health Policy. 2009;7(1):43-59. doi: 10.2165/00148365-200907010-00005.

PMID:
19558194
[PubMed - indexed for MEDLINE]
10.

Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil.

Burgess G, Hoogkamer H, Collings L, Dingemanse J.

Eur J Clin Pharmacol. 2008 Jan;64(1):43-50. Epub 2007 Nov 27.

PMID:
18040672
[PubMed - indexed for MEDLINE]
11.
12.

No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers.

Spence R, Mandagere A, Harrison B, Dufton C, Boinpally R.

J Pharm Sci. 2009 Dec;98(12):4962-74. doi: 10.1002/jps.21789.

PMID:
19455620
[PubMed - indexed for MEDLINE]
13.

Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells.

Gatfield J, Mueller Grandjean C, Sasse T, Clozel M, Nayler O.

PLoS One. 2012;7(10):e47662. doi: 10.1371/journal.pone.0047662. Epub 2012 Oct 15.

PMID:
23077657
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Differential vasoactive effects of sildenafil and tadalafil on cerebral arteries.

Kruuse C, Gupta S, Nilsson E, Kruse L, Edvinsson L.

Eur J Pharmacol. 2012 Jan 15;674(2-3):345-51. doi: 10.1016/j.ejphar.2011.10.037. Epub 2011 Nov 9.

PMID:
22094063
[PubMed - indexed for MEDLINE]
15.

Lack of pharmacodynamic interaction of silodosin, a highly selective alpha1a-adrenoceptor antagonist, with the phosphodiesterase-5 inhibitors sildenafil and tadalafil in healthy men.

MacDiarmid SA, Hill LA, Volinn W, Hoel G.

Urology. 2010 Mar;75(3):520-5. doi: 10.1016/j.urology.2009.10.042. Epub 2010 Jan 18.

PMID:
20080287
[PubMed - indexed for MEDLINE]
16.

The effects of PDE5 inhibitory drugs on renal ischemia/reperfusion injury in rats.

Küçük A, Yucel M, Erkasap N, Tosun M, Koken T, Ozkurt M, Erkasap S.

Mol Biol Rep. 2012 Oct;39(10):9775-82. doi: 10.1007/s11033-012-1843-1. Epub 2012 Jun 27.

PMID:
22736111
[PubMed - indexed for MEDLINE]
17.

Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil.

Mouchaers KT, Schalij I, de Boer MA, Postmus PE, van Hinsbergh VW, van Nieuw Amerongen GP, Vonk Noordegraaf A, van der Laarse WJ.

Eur Respir J. 2010 Oct;36(4):800-7. doi: 10.1183/09031936.00130209. Epub 2010 Mar 29.

PMID:
20351034
[PubMed - indexed for MEDLINE]
Free Article
18.

Safety and efficacy evaluation of ambrisentan in pulmonary hypertension.

Vizza CD, Fedele F, Pezzuto B, Rubin LJ.

Expert Opin Drug Saf. 2012 Nov;11(6):1003-11. doi: 10.1517/14740338.2012.714770. Epub 2012 Aug 4.

PMID:
22861496
[PubMed - indexed for MEDLINE]
19.

Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects.

Toque HA, Priviero FB, Zemse SM, Antunes E, Teixeira CE, Webb RC.

Clin Exp Pharmacol Physiol. 2009 Apr;36(4):358-66. doi: 10.1111/j.1440-1681.2008.05071.x. Epub 2008 Oct 15.

PMID:
18986324
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Endothelin receptor blockade combined with phosphodiesterase-5 inhibition increases right ventricular mitochondrial capacity in pulmonary arterial hypertension.

Mouchaers KT, Schalij I, Versteilen AM, Hadi AM, van Nieuw Amerongen GP, van Hinsbergh VW, Postmus PE, van der Laarse WJ, Vonk-Noordegraaf A.

Am J Physiol Heart Circ Physiol. 2009 Jul;297(1):H200-7. doi: 10.1152/ajpheart.00893.2008. Epub 2009 Apr 24.

PMID:
19395550
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk